Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis - 27/02/25
, Ashish Datt Upadhyay, PhD b, Koichi Izumikawa, ProfMD PhD c, Masato Tashiro, MD PhD c, Yuya Kimura, MD d, e, Felix Bongomin, MMed f, Xin Su, ProfMD PhD g, Thomas Maitre, MD PhD h, Jacques Cadranel, ProfMD PhD h, Vitor Falcao de Oliveira, MD i, Nousheen Iqbal, FCPS j, k, Muhammad Irfan, ProfFCPS k, Yurdagül Uzunhan, MD PhD l, Juan Aguilar-Company, MD PhD m, Oxana Munteanu, MD PhD n, Justin Beardsley, MB BS PhD o, Koji Furuuchi, MD PhD p, Takahiro Takazono, MD PhD c, Akihiro Ito, MD q, Chris Kosmidis, MD PhD r, s, David W Denning, ProfFRCP s, ⁎ Summary |
Background |
Despite antifungal treatment, chronic pulmonary aspergillosis (CPA) is associated with substantial morbidity and mortality. We conducted a systematic review and meta-analysis to evaluate rates of mortality and its predictors in CPA.
Methods |
A systematic literature search was conducted across MEDLINE (PubMed), Scopus, Embase, and Web of Science to identify studies in English, reporting mortality in CPA, from database inception to Aug 15, 2023. We included clinical studies, observational studies, controlled trials, and abstracts. Case reports, animal studies, letters, news, and literature reviews were excluded. Authors of studies published since 2016 were also contacted to obtain anonymised individual patient data (IPD); for other studies, summary estimates were extracted. Subgroup analysis was done for differences in overall 1-year and 5-year mortality, data source, study design, risk of bias, country, Human Development Index, age groups, and the underlying lung disease. We used random-effects meta-analyses to estimate pooled mortality rates. Subgroup analyses and meta-regression were done to explore sources of heterogeneity. One-stage meta-analysis with a stratified Cox proportional hazards model was used to estimate the univariable and hazards for mortality, adjusting for age, sex, type of CPA, treatment, and underlying pulmonary comorbidities. This study was registered with PROSPERO (CRD42023453447).
Findings |
We included 79 studies involving 8778 patients in the overall pooled analysis and 15 studies involving 1859 patients in the IPD meta-analysis. Pooled mortality (from 70 studies) was estimated at 27% overall (95% CI 22–32; I2 =95·4%), 15% at 1 year (11–19; I2 =91·6%), and 32% at 5 years (25–39; I2 =94·3%). Overall mortality in patients with CPA with pulmonary tuberculosis as the predominant predisposing condition was 25% (16–35; I2 =87·5%; 20 studies) and with chronic obstructive pulmonary disease was 35% (22–49; I2 =89·7%; 14 studies). Mortality in cohorts of patients who underwent surgical resection was low at 3% (2–4). In the multivariable analysis, among predisposing respiratory conditions, pulmonary tuberculosis history had the lowest mortality hazard (relative to an absence of the disease at baseline), whereas worse outcomes were seen with underlying malignancy; subacute invasive pulmonary aspergillosis and chronic cavitary pulmonary aspergillosis subtypes of CPA were also significantly associated with increased mortality relative to simple aspergilloma on multivariable analysis. Mortality hazard increased by 25% with each decade of age (adjusted hazard ratio 1·25 [95% CI 1·14–1·36], p<0·0001).
Interpretation |
CPA is associated with substantial mortality. Advancing age, CPA subtype, and underlying comorbidities are important predictors of mortality. Future studies should focus on identifying appropriate treatment strategies tailored to different risk groups.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 3
P. 312-324 - mars 2025 Retour au numéro
Article précédent
- Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study
- Slim Fourati, Alawiya Reslan, Jérome Bourret, Jean-Sébastien Casalegno, Yannis Rahou, Lionel Chollet, Sylvie Pillet, Pauline Tremeaux, Nefert Candace Dossou, Elyanne Gault, Maud Salmona, Berthe-Marie Imbert-Marcille, Audrey Mirand, Sylvie Larrat, Alice Moisan, Stéphane Marot, Aurélie Schnuriger, Nicolas Veyrenche, Ilka Engelmann, Lynda Handala, Amandine Henry, Valentin Stephan, Ségolène Brichler, Véronique Avettand-Fenoel, Nael Zemali, Caroline Lefeuvre, Charlotte Pronier, Luc Deroche, Marie-Christine Jaffar-Bandjee, Lina Mouna, Catherine Francois, Alexandre Regueme, Cédric Hartard, Sylvie Rogez, Floriane Gallais, Arnaud Ly, Christophe Rodriguez, Georges Dos Santos, Etienne Simon-Loriere, Olivier Schwartz, Julian Buchrieser, Jean-MiIchel Pawlotsky, Frédéric Lemoine, Etienne Audureau, Marie-Anne Rameix-Welti, POLYRES investigators, Naël Zemali, Sonia Burrel, Alice Moisan, Zakasoa-Mbololona Zavaoarisaina, Romain Legros, Boris Derman, Vincent Pargny, Hortense Petat, Jean-Christophe Plantier, Véronique Avettand-Fenoel, Salim Ferrani, Jérome Guinard, Clémence Guillaume, Gilbert Mchantaf, Victoria Marie, Laurent Bret, Fabien Lesne, Anthony de Oliveira, Alexandre Regueme, Kazali Alidjinou, Lionel Chollet, Vincent Gardan, Ségolène Brichler, Loic de Pontual, Camille Aupiais, Stéphane Marot, Aurélie Schnuriger, Marine Perrier, Pierre Jatteau, Djeneba Fofana, Théophile Cocherie, Elisa Teyssou, Cathia Soulié, Vincent Calvez, Sylvie Larrat, Anne Faisant, Guillaume Mortamet, Caroline Tournegros, Mohamed Habib, Sylvie Pillet, Aymeric Cantais, Franck Zekre, Thomas Bourlet, Oulfa Boussetta-Charfi, Sara Chenafi-Adham, Eva Gleizes, Cédric Hartard, Caroline Lefeuvre, Elise Bouthry, Lina Mouna, Fairly Warnakulasuriya, Quentin Le Hingrat, Marie-Christine Jaffar, Diana Heaugwane, Benjamin Azemar, Nicolas Mnemosyme, Laurent Souply, Catherine François, Sandrine Castelain, Cinthia Rames, Arnaud Bécourt, Ilka Engelmann, Eric Jeziorski, Vincent Foulongne, Steven Henry, Léa Domitien, Lynda Handala, Catherine Gaudy-Graffin, Agathe Crémadés, Amandine Henry, Alessandra Pennisi, Maud Salmona, Jérôme Le Goff, Sarah Mafi, Audrey Gabassi, Marie-Laure Néré, Stéphane Bonacorsi, Naim Ouldali, Senhaji Rachik Abdeljalil, Marie-Anne Rameix-Welti, Alawyia Reslan, Yannis Rahou, Jérome Bourret, Frédérique Lemoine, Kévin Da Silva, Samar Berreira Ibraim, Emilie Yab, Vincent Enouf, Flora Donati, Matthieu Prot, Banujaa Jeyarajah, Etienne Simon-Loriere, Nefert Candace Dossou, Astrid Vabret, Slim Fourati, Christophe Rodriguez, Jean-Michel Pawlotsky, Pierre Cappy, Alexandre Soulier, Mohamed Ader, Sarah Seng, Arnaud Ly, Pierre-André Natella, Etienne Audureau, Georges Dos Santos, Laurence Fagour, Anne-Julie Schapira, Olivier Flechelles, Luc Deroche, Nicolas Leveque, Claire Morton Fauche, Berthe-Marie Imbert, Louise Castain, Audreay Rodallec, Justine Sourice, Christele Gras-le Guen, Anne Chauvire-Drouard, Elyanne Gault, Frédérique Moreau, Claire Deback, Floriane Gallais, Morgane Solis, Valentin Stephan, Léa Pilorgé, Sophie Vallet, Léa Gaitan, Sylvie Rogez, Audrey Mirand, Cecile Henquell, Charlotte Pronier, Vincent Thibault, Pauline Trémeaux, Isabelle Claudet, Mélanie Pucelle, Laetitia Staes, Camille Vellas, Romain Carcenac, Nicolas Veyrenche, Jean-sébastien Casalegno, Alexandre Gaymard, Jose Kombou, Antonin Bal, Stanislas Ogoudjobi
- Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows
- Rebecca E Colman, Marva Seifert, Andres De la Rossa, Sophia B Georghiou, Christine Hoogland, Swapna Uplekar, Sacha Laurent, Camilla Rodrigues, Priti Kambli, Nestani Tukvadze, Nino Maghradze, Shaheed V Omar, Lavania Joseph, Anita Suresh, Timothy C Rodwell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?